This website is intended for US Healthcare Professionals.


The agents listed below are currently under investigation. Their safety and effectiveness have not yet been established.

Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Estrogen Receptor+/Human Epidermal Growth Factor Receptor 2-Advanced Breast Cancer: Update of Dose Escalation Results From a Phase 1/2 Trial
EP Hamilton et al.
Phase 1/2 Study of Bavdegalutamide, a PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer: Radiographic Progression-Free Survival in Patients With Androgen Receptor Ligand-Binding Domain Mutation
DP Petrylak et al.

Arvinas Oncology Medical

You are now leaving Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

Arvinas Oncology Medical

This website is intended for US Healthcare Professionals. It includes educational resources related to Arvinas’ investigational agents, research, and therapeutic areas of interest.

By selecting continue below, you acknowledge the information above and certify that you are a US Healthcare Professional (HCP).

If you are a member of the public who would like to learn more about Arvinas’ investigational drugs click below to be directed to